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Abstract
Background: The steroid hormone testosterone has been found to be greatly reduced by opioids in different
experimental and clinical conditions. The purpose of this study on male rats was to determine the effects of a
single injection of morphine (5 mg/Kg) on persistent pain (formalin test) and the single or combined effects on
p450-aromatase and 5-alpha reductase type 1 mRNA expression in the brain, liver and testis. Testosterone was
determined in the plasma and in the brain, morphine was assayed in the plasma.
Results: In the morphine-treated rats, there were increases of 5-alpha reductase mRNA expression in the liver and
aromatase mRNA expression in the brain and gonads. Morphine was detected in the blood of all morphine-treated
rats even though there were no clear analgesic affects in the formalin-treated animals three hours after treatment.
Testosterone was greatly reduced in the plasma and brain in morphine-treated subjects.
Conclusions: It appears that morphine administration can induce long-lasting genomic effects in different body
areas which contribute to the strong central and peripheral testosterone levels. These changes were not always
accompanied by behavioral modifications.
Background
It has repeatedly been shown in vitro and in vivo that
opioids change gonadal hormones after treatment,
resulting in a dramatic alteration of the hormones ratio
[1,2]. In particular we have shown that testosterone (T)
levels are significantly decre a s e db ym o r p h i n ei n d e p e n -
dently of the duration of treatment and with clear clini-
cal signs (fatigue, anemia) [3,4]. This clear long-lasting
depressant effect has been attributed to direct inhibition
of morphine at hypothalamic levels: i.e. a decrease of
gonadotropin releasing hormone (GnRH) followed by a
decrease of T production by the testis [5]. More recently
this hypothesis was supported by evidence showing an
involvement of other neural and metabolic structures in
which T-catabolic enzymes were modulated by opioids,
suggesting increased catabolism of this hormone able to
explain its fast disappearance from the blood [6-8].
Indeed, although not related to pain, steroid hormones
and opioid interactions in the brain have been exten-
sively described [9].
T is produced by the testis but can also be obtained
from other metabolic pathways present in other body
structures, including the brain [10]. Its action is wide-
spread and includes peripheral and central effects
obtained with classic genomic or rapid membrane-
mediated actions [11]. Testosterone can bind directly to
androgen receptors (ARs) or can be aromatized to estra-
diol (E2), acting on estrogen receptors (ERs), or reduced
to dihydrotestosterone (DHT), acting on ARs. These
metabolites (E2 and DHT) play crucial roles in the
organism, mediating many functions such as cognition,
reproduction, feeding, muscle, blood and brain metabo-
lism [12,13]. Thus modulation of the enzymes 5-alpha
reductase and aromatase has to be considered an impor-
tant gateway to these functions. The former plays an
important role in testosterone conversion to DHT in
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any medium, provided the original work is properly cited.androgen-dependent tissue, the latter in T aromatization
to E2. Two 5-alpha reductase isoenzymes have been
characterized in rats: type 1 and type 2, reported to play
a catabolic and an anabolic role on T, respectively. In
this experiment we study the mRNA expression of 5-
alpha reductase type 1 (5aR-1) and p450-aromatase
(AROM). AROM is primarily expressed in the hypotha-
lamus and limbic regions of the brain. The peripheral
expression of aromatase is widely distributed. Early stu-
dies on aromatization in the hypothalamus of male and
female rats were reported by Naftolin [14].
Pain therapy with opioid drugs is based on their abil-
ity to bind opioid receptors in the CNS and in the per-
iphery; in particular, through its binding to opioid
receptors, morphine is known to act in several body
regions from the gut to the brain [15,16]. Previous stu-
dies have clearly shown that morphine induces a long-
lasting decrease of T even if treatment lasts for months
or years [4]. The effect can be induced by low and
subanalgesic concentrations of morphine and occurs
after a few hours. We have also shown that once treat-
ment is interrupted the levels recover in a few hours/
days [3,17].
To evaluate their relative expression and modulation
by morphine and pain, 5aR-1 and AROM were deter-
mined in the diencephalon, liver and testis. While the
diencephalon is the key structure to be studied in view
of the long-term effects that can be produced by T
deficiency [18], the liver and testis are peripheral struc-
tures representing its main site of production (testis)
and degradation (liver). Behaviors were recorded and
analyzed during the formalin test while T was deter-
mined at the end of the test in blood and brain
samples.
Results
The behavioral analysis carried out during the formalin
test showed that spontaneous behaviors were affected by
morphine although recorded three hours after adminis-
tration (Figure 1A, B), whereas as expected the adminis-
tration of a subanalgesic concentration of morphine did
not produce any significant modification in formalin-
induced pain responses (Figure 1C, D, E). Morphine was
present in the blood at detectable levels at the end of
the experiment, four hours after treatment (Figure 2).
The blood testosterone levels were strongly decreased
in the formalin and/or morphine-treated groups (p =
0.01 and p < 0.001, respectively) but not in the saline-
treated ones (Figure 3A); testosterone was not detected
in the brain in both morphine-treated groups (Figure
3B). The comparison between the two saline-treated
groups (T-Student) revealed significantly lower testoster-
one levels (p < 0.05) in the SAL/FORM group than in
the SAL/SHAM one.
5-alpha reductase (5aR-1) and aromatase (AROM) mRNA
expression
Figure 4 reports the relative mRNA expression of 5aR-1
and AROM in the diencephalon, liver and testis in the
control group. Our data indicate that 5aR-1 expression
was much higher in the diencephalon than in the liver
(used as reference, i.e. 1) while its expression in the tes-
tis was only half that in the liver. In contrast, AROM
expression in the diencephalon was about 10% of that in
the liver and the levels in the testis were very low
(about 2%). The ratio among these three tissues is
important because it indicates whether the stimulus
used affects only their absolute activity or also changes
the relative activities of the enzymes in the different
tissues.
Figure 5 shows the relative mRNA expression of 5aR-1
and AROM in the diencephalon, liver and testis in all
groups. The 5aR-1 mRNA expression in the diencepha-
lon differed among groups (p < 0.012); it was 100%
higher in the MOR/SHAM group than in the others
(p < 0.05) while in MOR/FORM the increase was smal-
ler and not significant. In the same tissue there was an
effect of Treatment (p < 0.001) on AROM expression
due to its upregulation in both morphine groups
Figure 1 Behaviors recorded during the formalin test (60 min).
Spontaneous behaviors: (A) activity duration (sec) and (B) rearing
frequency (n). Pain-related behaviors: (C) flexing duration, (D) licking
duration and (E) paw-jerk frequency recorded in male rats treated
with morphine (MOR) or saline (SAL) three hours before the
formalin test in the dorsal hind paw. Data are shown as mean ±
SEM.
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expression was independent of pain.
In the liver, the 5aR-1 mRNA expression was
increased (p < 0.001 per all) about fourfold by formalin
and/or morphine treatment (p < 0.001) while the
AROM expression was significantly decreased in the
S A L / F O R Mg r o u p( p<0 . 0 5 )a n du n c h a n g e di nt h e
other groups.
In the testis, no differences in 5aR-1 gene expression
were observed among groups. In contrast the AROM
mRNA expression showed a marked change in all
groups when compared to the SAL/SHAM group (p =
0.0001); in SAL/FORM the increase was about twofold
(p < 0.01) while in both morphine groups the increase
was about fourfold (p < 0.001).
Discussion
The main result of the present experiment is that the
expression of 5-alpha reductase type 1 (5aR-1) and
p450-aromatase (AROM) in the male rat brain, liver and
testis was strongly affected by inflammatory pain and
morphine. These changes, which differed among the tis-
sues, were not accompanied by evident changes in pain
behaviors but by a clear decrease of testosterone (T)
levels in the blood and diencephalon.
The main cause of these immediate and long-lasting
effects has been attributed to the inhibitory action of
morphine on gonadotropin-releasing hormone secretion
in the hypothalamus [see 3]. This inhibition is able to
decrease gonadotropin production and then gonadal
Figure 2 Morphine levels in SHAM and FORM groups four
hours after a single injection of morphine. Data are shown as
mean ± SEM. Insert: calibration curve for morphine. The levels were
comparable between the two groups.
Figure 3 Testosterone plasma (A) and brain (B) levels
determined four hours after treatment in morphine (MOR)-
treated animals and controls (SHAM); in formalin (FORM)-
treated animals and controls (SHAM). Data are shown as mean ±
SEM.
Figure 4 Relative mRNA expression of 5-alpha reductase type
1 and p450-aromatase in the diencephalon, liver and testis of
the control group (SAL/SHAM). Liver is the reference organ,
indicated as 1. Data are shown as mean ± SEM.
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morphine-induced hypogonadism, observed in patients
treated with this drug, is not merely centrally mediated
and that other ‘peripheral’ active sites must be consid-
ered. Thus it was decided to study testosterone catabolic
enzymes in order to indicate the changes occurring in
that system. We showed upregulation of AROM activity
in astrocytes in vitro[6] and Amini et al. [7] demon-
strated an increase of 5-alpha reductase expression in
vivo. In agreement with the previous data and with our
initial hypothesis, we showed in the present experiment
that a single s.c. injection of morphine changed the
aromatase activity in two of the three tissues taken into
account, strongly indicating an increase of the catabolic
activity of testosterone at least in these tissues.
The high AROM mRNA expression observed in the
diencephalon and testis suggests an increase in enzy-
matic activity resulting in increased metabolism of tes-
tosterone to estradiol (E2). The role of estrogens in the
nervous system is well known; in male and female sub-
jects, many neural circuits are modulated by these hor-
mones. In particular, E2 shows close interactions (cross-
talk), cross-coupling and reciprocal regulation with pro-
teins involved in signal transduction mediated by neural
Figure 5 5-alpha reductase type 1 (A) and p450-aromatase (B) mRNA expression in the diencephalon, liver and testis. SAL/SHAM is the
reference group, indicated as 1. Data are shown as mean ± SEM. Statistical significance vs SAL/SHAM *p < 0.05; **p < 0.01; ***p < 0.001.
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over, estrogens play a role in activation of the molecular
cascade involved in plastic adjustment of cellular func-
tions inducing c-Fos expression (one of the first signs of
neuronal plasticity) in the hippocampus [22], activate
MAP-kinase (a growth factor) [23] and potentiate gluta-
mate binding to N-methyl-d-aspartate (NMDA) recep-
tors [20,21]. Thus it appears that the structural and
functional changes induced by E2 help to increase sei-
zure (pain or stress) susceptibility. On the other hand,
estrogens were shown to limit neuronal damage and
death, possibly by signaling through PI3K, PKC, ERK or
glycogen synthase kinase 3-b [24]. In the testis,A R O M
is responsible for the transformation of androgens into
estrogens using either androstenedione or T as andro-
genic substrates, which are aromatized to estrone (E1)
and E2, respectively [25]. This activity can be explained
b yt h en e e dt oi n c r e a s eE 2 in these structures actively
involved in the regulation of reproductive testis func-
tions [26]. Interestingly, AROM expression was not
affected by morphine treatment in the liver. This is
important since this enzyme is the one used to metabo-
lize codeine to morphine in the same tissue [27].
In the present study we also determined the expres-
sion of 5aR-1, the other enzyme involved in testosterone
degradation, in the same tissues. The expression was
affected by morphine in the diencephalon and liver but
not in the testis. 5aR-1 acts on T to produce DHT. In
the CNS, DHT was found to have particular organiza-
tional effects on selected neuronal populations [28]. At
the cellular level, the direct role of androgens in the
brain is supported by the observation that both T and
DHT modify the number of branching points in preop-
tic neurons in culture [29], acting particularly as mor-
phogenetic signals for the developing hypothalamic
neurons containing AROM and thus influencing the
plasticity and synaptic connectivity of the hypothalamic
aromatase system [30]. The activational effects of DHT
on cognition have been far less studied than the effects
of T. It has been shown, however, that DHT is a power-
ful steroid in the CNS with a fourfold higher affinity to
the human ARs than T [31]. Recently, Cherrier et al.
[32] prospectively examined changes in cognition in
hypogonadal men given T and older hypogonadal men
given DHT; they demonstrated significant improvements
in verbal memory in response to T supplementation
with increased serum levels of T, DHT and E2 (second-
ary to aromatization), although the increases in spatial
memory did not reach statistical significance. In older
hypogonadal men, DHT treatment, with increased DHT
and decreased T serum levels, resulted in a significant
improvement in spatial memory. These findings are sup-
ported by research on male rats in which there was an
increase in spine synapse density in the CA1 sub-field of
the hippocampus after treatment with testosterone pro-
pionate (TP) or DHT [33].
An interesting point to consider are the effects
induced on T and its enzymes by formalin pain per se.
T levels were decreased in the brain and blood of for-
malin-treated animals. It should be noted that formalin
pain per se decreased AROM and increased 5aR-1
expression in the liver. This appears to be an important
shift in the metabolic pathways: DHT production seems
to be preferred to E2, in line with the observation by
Negri-Cesi et al. [34] who showed a decrease in AROM
activity in hypothalamic male rat neurons exposed to
DHT in vitro.
In our adult male rats, AROM was much more highly
expressed in liver than in the diencephalon and testis;
nevertheless, its physiological role is not very clear since
liver is generally considered a non-steroidogenic tissue
[35,36]. However the huge increase in 5aR-1 in the liver
can be explained by the need to eliminate androgens
and protect against excessive hormone levels; the path-
way responsible for the switch from T to DHT activity
involves the irreversible reaction catalyzed by this
enzyme [37].
Another point is the lack of any changes in formalin-
induced pain in morphine-treated animals. Therefore
the morphine-induced changes in gonadal hormone
metabolism would be able by themselves to completely
cancel the expected analgesic effect of the morphine.
This is in agreement with Nagypal et al. [38] who pro-
vided neuroanatomical evidence that T-induced brain
activation overlaps with opiate-responsive regions; T
may activate opiate-responsive neurons directly or indir-
ectly via metabolites to facilitate reinforcement. It
appears that once morphine enters the body it acts to
increase the production of these metabolites. However
the low T levels in both humans and experimental ani-
mals treated with morphine suggest that this effect
would be useful in the short term (i.e. during an acute
stress with the release of endogenous opioids), whereas
the longer lasting effects obtained with pain therapy
would not be useful and could initiate a series of nega-
tive effects well known to pain therapists.
Conclusions
In the present study we determined the gene expression
of the two main catabolic enzymes of T and we showed
that morphine treatment significantly changes 5aR-1
and AROM mRNA expression in different body regions.
There was a significant increase in the expression of one
or both of these enzymes in the brain as well as in the
liver and testis, suggesting a pro-metabolic action of
morphine. Hence T is not only produced to a lesser
degree because of the well known opioid effects on
gonadotropin secretion, it is also metabolized to a
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brain levels. At present this evidence cannot be consid-
ered negative since both E2 and DHT can have benefi-
cial effects on neurons, although detrimental effects
have also been described [39]. The very low (n.d.) levels
of T in the brain suggest that when T levels are very
low in the blood the possibility of this hormone being
present in the brain is very low [8]. We have recently
shown in vitro that supplementation of astrocytes with
exogenous T strongly increases the testosterone cell
content [6]. Thus, although the production of T in the
CNS is possible, the exogenous supplementation of this
hormone would play an important role in maintaining
acceptable levels and functions.
Methods
Subjects
Thirty-five gonadally intact male Sprague-Dawley rats
(Harlan, Italy), weighing 320-400 g, were used. The ani-
mals were housed in groups (4 per cage) in plastic-bot-
tomed cages with sawdust bedding and kept at room
temperature 21 ± 1 C°, relative humidity 60 ± 10% and
a 12/12 h light/dark cycle. They received food and water
ad libitum. Lights went off at 07:00 a.m. and testing was
carried out between 09:30 a.m. and 12:30 p.m. during
the dark phase, the active period of rodents. The experi-
mental procedures were pre-approved by the Ethics
Committee of the University of Siena. In all experi-
ments, attention was paid to the regulations for hand-
ling laboratory animals of the European Communities
Council Directive (86/609/EEC) and the Ethical Guide-
lines for investigation of experimental pain in conscious
animals issued by the ad-hoc Committee of the Interna-
tional Association for the Study of Pain [40]. Particular
efforts were made to minimize animal suffering and to
reduce the number of animals used.
Materials and Reagents
All chemicals were reagent or HPLC grade from Sigma-
Aldrich (St. Louis, MO) with the exception of the mor-
phine (S.A.L.A.R.S., Como, Italy) and morphine-d3 from
Lipomed AG (Arlesheim, CH).
Groups
The animals were randomly assigned to four experimen-
tal groups:
￿SAL/SHAM (n = 11, rats treated with saline and
sham-injected in the formalin test),
￿SAL/FORM (n = 8, rats treated with saline and for-
malin-injected in the formalin test),
￿MOR/SHAM (n = 8, rats treated with morphine
and sham-injected in the formalin test),
￿MOR/FORM (n = 8, rats treated with morphine
and formalin-injected in the formalin test).
Treatment
Treatment consisted of injection of morphine (5 mg/Kg)
or saline (NaCl 0.9%) into the subcutaneous tissue of
the back while the animals were gently restrained. A
mean volume of 220 μl was injected subcutaneously
(s.c.) into each animal. Immediately after the injection
the rats were returned to their home cage to rejoin the
original group.
Formalin test (FT)
Three hours after the morphine or saline injection the
rats were randomly assigned to SHAM or FORM
groups. FORM animals received dilute formalin (10%,
50 μl) s.c. in the right dorsal hind paw. Sham animals
were merely pricked with the syringe needle, without
injection of any substances. The rat was then placed in
the Open Field apparatus and its behavior was recorded
for 60 min. To determine pain intensity and to verify
the behavioral effects of treatment, pain-related and
spontaneous behaviors were considered:
a) pain-related behaviors (formalin-induced responses):
licking duration (time spent licking the injected foot);
flexing duration (time spent with the leg held off the
floor, flexed close to the body); paw-jerk frequency
(number of phasic flexions of the leg).
b) spontaneous behaviors: rearing frequency (number
of times the animal stood on its fore limbs); activity
duration (time spent sniffing and looking around the
environment, even the time spent washing or scratching
the face or body).
Parameters
A tt h ee n do ft h ef o r m a l i nt e s tt h er a t sw e r ea n e s t h e -
tized with sodium pentobarbital, the abdomen was
opened and blood was collected from the abdominal
vein in EDTA-added syringes. The animals were intra-
cardially perfused with phosphate buffered saline (PBS,
about 200 ml) for exsanguinations of the CNS. Then the
diencephalon, the gonads and part of the liver were dis-
sected and frozen till gene expression determination.
The blood was centrifuged and the plasma was divided
into aliquots and immediately frozen till morphine and
hormonal determinations.
Morphine determination
Solid phase extraction (SPE) was performed with dispo-
sable ISOLUTE® non-polar SPE sorbents (Biotage) to
extract acidic, basic or neutral drugs from biological
fluids using a non-polar (hydrophobic) retention
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cartridges were conditioned with 2 ml of MeOH and 2
ml of borate buffer (pH 9; 50 mM) using vacuum
aspiration. 250 μl of plasma were added to 500 μlo f
borate buffer (pH 9; 50 mM). This solution was loaded
onto the cartridges and slowly drawn through them.
The cartridges were sequentially washed with 1 ml of
water/methanol (95:5) and twice with 500 μlo fa c i d i c
MeOH (formic acid 2%, v/v) using vacuum aspiration.
Finally, the sample was dried under N2 and reconsti-
tuted with 250 μl of solution used for the mobile phase
LC-MS/MS analysis. Before SPE, an internal standard
(IS) of morphine-d3 was added to all plasma samples at
a concentration of 20 ng/ml.
The analysis was performed with a Varian chromato-
graphic instrument (Varian Inc.) operated by the Varian
MS Workstation software system Control Vers 6.9, con-
sisting of a binary pump (212-LC) detector connected
to a Varian triple quadrupole (LC-MS 320/MS) with
ESI ionization source. The sample for the chromato-
graphic analysis was obtained under the conditions
described above. For the chromatographic analysis, a
Pursuit C18 column (3 μm 100 × 2 mm) (Varian) was
used. The mobile phase consisted of: (A) 1% formic
acid in water plus 3 mM ammonium acetate; and (B)
HPLC grade methanol. A linear gradient from 90% A to
10% A in 8 min was used and after 2 min the gradient
returned to 90% A for 5 min. The column temperature
was maintained at room temperature. The injection
volume was 10 μl; run time was 16 min; flow rate was
0.2 ml/min. The mass spectrometer was operated in the
positive mode. Quantification was performed using
selected reaction monitoring (SRM) of the transitions of
the precursors to the product ions as follows: mass-to-
charge ratio (m/z) 286 ® 201 for morphine and (m/z)
289 ® 201 for morphine-d3 (internal standard (IS)),
with a scan time of 0.3 s per transition. The tuning
parameters were optimized for morphine by infusing a
solution containing 1 μg/ml of analyte at a flow rate of
10 μl/min into the mobile phase (0.2 ml/min) using a
post-column “T” connection. The optimal MS para-
meters obtained were as follows: the spray voltage was
5 0 0 0Vw i t has o u r c eC I Dv o l t a g eo f1 0e V ,t h eh e a t e d
capillary was 350°C. Nitrogen was used as the sheath
gas (45 psi) and auxiliary gas (19 psi). Argon was used
as the collision gas at a pressure of approximately 1.80
mtorr. The optimized collision energy chosen for mor-
phine was 19 eV. The concentration of morphine in the
samples was calculated in comparison with the peak
area of morphine-d3 (IS) and each sample was analyzed
in triplicate. For all samples the mean, standard devia-
tion and coefficient of variation (always less than 15)
were also calculated.
RNA extraction and real-time quantitative reverse
transcription PCR
Total RNA from liver, diencephalon and testis was
extracted and purified with a NucleoSpin RNA II kit
(Macherey-Nagel GmbH&Co KG, Germany) following
the manufacturer’s instructions. The RNA concentration
was measured with a NanoDrop ND-100 spectrophot-
ometer. qRT-PCR was performed to monitor the gene
expression levels of 5-alpha reductase type 1 and p450-
aromatase. Five hundred nanograms of RNA were
reverse transcribed with the Transcriptor High Fidelity
cDNA Synthesis kit (Roche, Mannheim, Germany) using
oligo (dT) primers (Roche). One microliter of the cDNA
was amplified using Opticon II (MJ Research, Waltham,
MA) and the SYBR Green PCR Master Mix (Applied
Biosystems, Warrington, UK), following the manufac-
turer’s instructions. Forty PCR cycles were performed
using an annealing temperature of 60°C for all the genes
tested. Primers were specifically designed between two
adjacent exons (AutoPrime program) and the sequences
used in this study were: for 5-alpha reductase,
CGTCCTGCTGGCTATGTTTC (forward), GAAGGC-
CAAGACAAAGGTGA (reverse); for p450-aromatase,
CGAGATCGAAATTCTGGTGGAAAAG (forward),
TGCAAAATCCTACAGTCTTCCAGTT (reverse); for
cyclophilin (housekeeping gene), ACACGCCA-
TAATGGCACTGG (forward), ATTTGCCATGGA-
CAAGATGCC (reverse).
Normalization of real-time PCR quantification
mRNA levels for 5-alpha reductase and P450-aromatase
(Ct) were normalized to cyclophilin by subtracting the
Ct value of the reference gene (cyclophilin) from the Ct
value of the samples (ΔCt = Ct sample-Ct reference). The
relative expression of the target gene to a calibrator is
quantified using 2
-ΔΔCt [41]. The calibrator was defined
as liver tissue the first time and as diencephalon or liver
or testis for the other comparative analysis. Finally the
relative expression was determined by subtracting the
ΔCt calibrator (ΔCt calibrator =C tcalibrator-Ct reference) from
the ΔCt value (ΔΔCt = ΔCt calibrator-ΔCt).
Testosterone determination in blood and brain
Blood and brain testosterone levels were extracted and
determined by radioimmunoassay (RIA) according to
different methods [42-44], revised and adapted [17].
Samples were assayed in duplicate.
Statistical analysis
Data were expressed as mean ± SEM. ANOVA was
applied with the factors Treatment (two levels: SAL,
MOR) and Pain (two levels: SHAM, FORM), followed
by Fisher’s protected least significant difference (PLSD)
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compare morphine concentrations in the two morphine-
treated groups. The criterion for statistical significance
was p < 0.05.
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